Further studies will be done in other breast cancer cell lines and cardiomyocytes (i.e., primary ventricular cardiomyocytes) exposed to CTLA-4 blocking agents as well as other immune check point inhibitors (PD-1 or PDL-1 blocking agents). This evidence concerns the gene PDCD1 and breast cancer.